Development of F-18 - Labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia

Radiology

Volumn 194, Issue 3, 1995, Pages 795-800

  Yang, David J ^a   Wallace, Sidney ^a   Cherif, Abdallah ^a   Li, Chun ^a   Gretzer, Matthew B ^a   Kim, E Edmund ^a   Podoloff, Donald A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Contrast media, comparative studies; Emission CT (ECT); Hypoxia; Neoplasms, blood supply

Indexed keywords

1 (4 FLUORO 2,3 DIHYDROXYBUTYL) 2 NITROIMIDAZOLE F 18; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORODEOXYGLUCOSE F 18; MISONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG TISSUE LEVEL; FEMALE; HYPOXIA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PARTITION COEFFICIENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT;

ANIMAL; AUTORADIOGRAPHY; CELL HYPOXIA; COMPARATIVE STUDY; CONTRAST MEDIA; FEMALE; FLUORINE RADIOISOTOPES; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MISONIDAZOLE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NITROIMIDAZOLES; RABBITS; RATS; RATS, INBRED F344; SUPPORT, NON-U.S. GOV'T; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0028917959     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.194.3.7862981     Document Type: Article

References (27)

1. Bush RS, Jenkins RDT, Allt WC, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 1978; 37(suppl III):302-306.
2. Clifford KH, Briggs RL, Stone HB. Quantitative radiosensitivity studies of solid carcinoma in vivo: methodology and effect of anoxia. J Natl Cancer Inst 1965; 36:965-974.
3. Dische S. A review of hypoxic-cell radiosensitization. Int J Radiat Oncol Biol Phys 1991; 20:147-152.
4. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissue at the time of irradiation as a factor in radiotherapy. Br J Cancer 1953; 26: 638-642.
5. Hall J. The oxygen effect and reoxygenation. In: Hall J, ed. Radiobiology for the radiobiologist. 3rd edition. Philadelphia, Pa: Lippincott, 1988; 137-160.
6. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993; 26:45-50.
7. Martin FD, Porter A, Fischer JJ, Rockwell S. Effect of a perfluorochemical emulsion on the radiation response of BA1112 rhabdomyosarcomas. Radiat Res 1987; 112:45-53.
8. Martin DF, Porter A, Rockwell S, Fischer JJ. Enhancement of tumor radiation response by the combination of a perfluorochemical emulsion and hyperbaric oxygen. Int J Radiat Oncol Biol Phys 1987; 13:747-751.
9. Morton JD, Porter E, Yabuki H, Nath R, Rockwell S. Effects of a perfluorochemical emulsion on the response of BA 1112 rat rhabdomyosarcomas to continuous low-dose-rate irradiation. Radiat Res 1990; 124:178-182.
10. 192Ir for continuous low-dose-rate radiation of BA1112 rat sarcomas. Radiat Res 1989; 119:478-488.
11. Moulder J, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis and a survey of existing data. Int J Radiat Oncol Biol Phys 1984; 10:695-712.
12. Peters LJ, Withers HR, Thames HD, Fletcher GH. Keynote address: the problem-tumor radioresistance in clinical radiotherapy. Int J Radiat Oncol Biol Phys 1982; 8:101-108.
13. Cherif A, Yang DJ, Tansey W, Kim EE, Wallace S. Synthesis of [F-18]fluoromisonidazole. Pharm Res 1994; 11:466-469.
14. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with F-18 fluoromisonidazole. Int J Radiat Oncol Biol Phy 1992; 22:199-212.
15. Valk PT, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with [F-18]fluoromisonidazole. J Nucl Med 1992; 33:2133-2137.
16. Martin GV, Caldwell JH, Rasey JS, Grunbaum Z, Cerqueia M, Krohn KA. Enhanced binding of the nypoxic cell marker [F-18]fluoromisonidazole in ischemic myocardium. J Nucl Med 1989; 30:194-201.
17. Rasey JS, Koh WJ, Grieson JR, Grunbaum Z, Krohn KA. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989; 17:985-991.
18. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characterization of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 1990; 122:301-308.
19. Brown JM, Workman P. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res 1980; 82:171-190.
20. McNeill TH, Koek LL, Brown SA, Hamill RW, Wu JY. Effect of misonidazole on neurotransmitter systems. Int J Radiat Oncol Biol Phys 1986; 12:1067-1070.
21. Yang DJ, Lahoda P, Brown PI, Rankin GO. Structure nephrotoxicity relationships for para-substituted N-phenylsuccinimides in Sprague-Dawley and Fischer 344 rats. Toxicology 1985; 36:23-35.
22. Moulder J, Martin GV. Hypoxic fraction determinations with the BA1112 rat sarcoma: variation within and among assay techniques. Radial Res 1984; 98:536-548.
23. Hall EJ. Radiosensitizers and bioreductive drugs. In: Radiobiology for the radiologist. Philadelphia, Pa: Lippincott, 1994; 165-181.
24. Yeh SH, Liu RS, Hu HH, et al. Ischemic penumbra in acute stroke: demonstration by PET with fluorine-18 fluoromisonidazole (abstr). J Nucl Med 1994; 35:205.
25. Yeh SH, Wu LC, Liu RS, Yang DJ, Yen SH, Yu TW. Fluorine-18 fluoromisonidazole tumor: muscle retention ratio in detecting hypoxia in nasopharyngeal carcinoma (abstr). J Nucl Med 1994; 25:142.
26. Liu RS, Yeh SH, Chang CP, et al. Detection of odontogenic infections by [F-18]fluoromisonidazole (abstr). J Nucl Med 1994; 35:113.
27. Martin GV, Caldwell JH, Graham MM, et al. Noninvasive detection of hypoxic myocardium using (F-18) fluoromisonidazole and positron emission tomography. J Nucl Med 1992; 33:2202-2208.